Sign In
Buy CMPGY
$32.39
+0.120 (+0.372%)
At Close: Jun 03, 2026
Compass Therapeutics: Finding Their Way With More Positive Updates In BTC
09:40am, Wednesday, 13'th Aug 2025
Compass Therapeutics' pipeline shows promise, especially with tovecimig's positive phase 2 results in biliary tract cancers and upcoming basket study plans. CTX-8371's early signals in NSCLC and TNBC
Compass Lexecon Ranked Top Economic Consulting Firm on Lexology Index Competition 2025 List
08:30am, Wednesday, 13'th Aug 2025
WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced that professionals from its Compass Lexecon subsidiary topped the Lexology Index: Competition 2025 list f
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
10:28pm, Tuesday, 12'th Aug 2025
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based
Compass Therapeutics Announces Proposed Public Offering
04:01pm, Tuesday, 12'th Aug 2025
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based
Compass Minerals Reports Fiscal 2025 Third-Quarter Results
04:30pm, Monday, 11'th Aug 2025
OVERLAND PARK, Kan.--(BUSINESS WIRE)--Compass Minerals (NYSE: CMP), a leading global provider of essential minerals, today reported fiscal 2025 third-quarter results. Unless otherwise noted, it should
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update
07:00am, Monday, 11'th Aug 2025
BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, to
Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
04:01pm, Friday, 08'th Aug 2025
BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, wi
Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA
06:30am, Tuesday, 05'th Aug 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass: Massive Leaps In Market Share
10:41am, Monday, 04'th Aug 2025
Compass' market share leaped to 6.09% in its most recent quarter, representing 96 bps of y/y expansion. The company achieved >20% growth in revenue, transactions, and transaction value, while the broa
Coinbase downgraded by Compass Point as Q2 results raise valuation concerns
07:45am, Monday, 04'th Aug 2025
Compass Point Research has downgraded Coinbase Global Inc. (NASDAQ: COIN) to sell from neutral, citing concerns over weakening earnings trends and a potentially overextended valuation. The move follow
Compass CEO: There's more housing inventory now than anytime in the last 6 years
11:45am, Thursday, 31'st Jul 2025
Compass CEO Robert Reffkin tells CNBC that housing inventory nationwide is back to where it was before the pandemic. But certain markets, like New York City, have seen rentals prices surge in the last
Compass CEO Robert Reffkin: There's more inventory than any time in the last six years
07:33am, Thursday, 31'st Jul 2025
Robert Reffkin, Compass CEO, joins 'Squawk Box' to discuss the company's quarterly earnings results, state of the real estate market, housing affordability concerns, and more.
Compass, Inc. (COMP) Q2 2025 Earnings Call Transcript
07:24am, Thursday, 31'st Jul 2025
Compass, Inc. (NYSE:COMP ) Q2 2025 Earnings Conference Call July 30, 2025 5:00 PM ET Company Participants Soham Jairaj Bhonsle - Head of IR Robert L. Reffkin - Founder, Chairman & CEO Kalani Reelitz -
Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights
06:30am, Thursday, 31'st Jul 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass, Inc. (COMP) Matches Q2 Earnings Estimates
07:06pm, Wednesday, 30'th Jul 2025
Compass, Inc. (COMP) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.04 per share a year ago.
